Plasma B-vitamins and one-carbon metabolites and the risk of breast cancer in younger women.
Ontology highlight
ABSTRACT: PURPOSE:We examined the association of plasma B-vitamins and metabolites, and related genetic variants, with risk of breast cancer among predominantly premenopausal women. METHODS:We conducted a nested case-control study within the Nurses' Health Study II. From blood samples collected in 1996-1999 and follow-up through 2007, plasma measures were available for 610 cases and 1207 controls. Unconditional multivariable logistic regression was used to estimate relative risks (RR) of breast cancer and 95% confidence intervals (CIs). We examined whether associations varied by methylenetetrahydrofolate reductase (MTHFR) and dihydrofolate reductase polymorphisms, breast cancer risk factors, or tumor characteristics. RESULTS:Plasma vitamin B12 was associated with a 64% higher risk of breast cancer comparing the highest versus lowest quintile (95% CI 1.17-2.29, p-trend?=?0.02). Plasma folate (comparable RR?=?1.18, 95% CI 0.84-1.66), pyridoxal 5'-phosphate (RR?=?1.18, 95% CI 0.85-1.64), homocysteine (RR?=?0.93, 95% CI 0.67-1.28), cysteine (RR?=?1.14, 95% CI 0.81-1.62), and cysteinylglycine (RR?=?0.93, 95% CI 0.66-1.31) were not associated with overall breast cancer risk. Folate was significantly positively associated with invasive and estrogen receptor-positive/progesterone receptor-positive breast cancer, and this association was suggestively stronger for bloods collected post-fortification. Several nutrient/breast cancer associations varied across subgroups defined by age, smoking, alcohol, multivitamin use, and MTHFR status (p-interaction?
SUBMITTER: Houghton SC
PROVIDER: S-EPMC6551273 | biostudies-literature | 2019 Jul
REPOSITORIES: biostudies-literature
ACCESS DATA